Pacira BioSciences (PCRX) Competitors $22.73 -0.58 (-2.49%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$22.81 +0.08 (+0.35%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRKShould you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry. Pacira BioSciences vs. Its Competitors Perrigo Supernus Pharmaceuticals Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the media prefer PCRX or PRGO? In the previous week, Pacira BioSciences had 1 more articles in the media than Perrigo. MarketBeat recorded 5 mentions for Pacira BioSciences and 4 mentions for Perrigo. Perrigo's average media sentiment score of 0.90 beat Pacira BioSciences' score of 0.77 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PCRX or PRGO more profitable? Perrigo has a net margin of -4.16% compared to Pacira BioSciences' net margin of -14.78%. Pacira BioSciences' return on equity of 13.78% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Pacira BioSciences-14.78% 13.78% 7.00% Perrigo -4.16%8.93%3.87% Do analysts rate PCRX or PRGO? Pacira BioSciences currently has a consensus price target of $26.44, indicating a potential upside of 16.34%. Perrigo has a consensus price target of $33.00, indicating a potential upside of 22.04%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pacira BioSciences 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do institutionals & insiders believe in PCRX or PRGO? 99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 0.4% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, PCRX or PRGO? Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPacira BioSciences$702.77M1.50-$99.56M-$2.28-9.97Perrigo$4.37B0.85-$171.80M-$1.31-20.64 Which has more volatility and risk, PCRX or PRGO? Pacira BioSciences has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. SummaryPacira BioSciences beats Perrigo on 11 of the 16 factors compared between the two stocks. Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition Export to ExcelMetricPacira BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-9.9720.2228.5419.58Price / Sales1.50299.17429.2495.01Price / Cash5.4043.1536.0257.93Price / Book1.357.568.145.54Net Income-$99.56M-$55.11M$3.24B$257.73M7 Day Performance-1.90%3.81%0.18%-0.08%1 Month Performance-6.61%11.60%5.96%8.09%1 Year Performance6.36%-2.11%26.24%13.02% Pacira BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.0723 of 5 stars$22.73-2.5%$26.44+16.3%+6.7%$1.08B$702.77M-9.97720PRGOPerrigo4.5387 of 5 stars$26.74-1.7%$33.00+23.4%+0.5%$3.74B$4.37B-20.418,379SUPNSupernus Pharmaceuticals1.5417 of 5 stars$31.45-1.7%$36.00+14.5%+16.6%$1.79B$661.82M28.33580Positive NewsNKTRNektar Therapeutics4.0271 of 5 stars$23.47-5.2%$84.17+258.6%+13.3%$307.20M$98.43M-2.45220Analyst RevisionHigh Trading VolumeOMEROmeros3.7624 of 5 stars$3.08-3.8%$18.00+484.4%-18.7%$187.50MN/A-1.16210Analyst RevisionGap DownASMBAssembly Biosciences3.5704 of 5 stars$18.56+2.3%$33.00+77.8%+21.3%$138.54M$28.52M-2.98100CPIXCumberland Pharmaceuticals0.8968 of 5 stars$3.04-3.5%N/A+139.7%$47.13M$37.87M-12.1680Trending NewsLLYEli Lilly and Company4.9789 of 5 stars$772.82-1.0%$1,011.61+30.9%-18.7%$739.87B$45.04B62.8847,000Trending NewsAnalyst RevisionJNJJohnson & Johnson4.9391 of 5 stars$155.23-0.5%$170.88+10.1%+4.1%$375.37B$88.82B17.27138,100Trending NewsABBVAbbVie4.7744 of 5 stars$187.44-1.0%$211.29+12.7%+11.0%$334.34B$56.33B79.7655,000Trending NewsAnalyst RevisionMRKMerck & Co., Inc.4.9962 of 5 stars$80.890.0%$109.19+35.0%-36.4%$203.22B$64.17B11.7775,000Positive News Related Companies and Tools Related Companies Perrigo Competitors Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCRX Stock Alerts